The innate sensor ZBP1-IRF3 axis regulates cell proliferation in multiple myeloma
Kanagaraju Ponnusamy,
Maria Myrsini Tzioni,
Murshida Begum,
Mark E. Robinson,
Valentina S. Caputo,
Alexia Katsarou,
Nikolaos Trasanidis,
Xiaolin Xiao,
Ioannis V. Kostopoulos,
Deena Iskander,
Irene Roberts,
Pritesh Trivedi,
Holger W. Auner,
Kikkeri Naresh,
Aristeidis Chaidos,
Anastasios Karadimitris
Affiliations
Kanagaraju Ponnusamy
Hugh and Josseline Langmuir Centre for Myeloma Research, Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London
Maria Myrsini Tzioni
Hugh and Josseline Langmuir Centre for Myeloma Research, Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London
Murshida Begum
Hugh and Josseline Langmuir Centre for Myeloma Research, Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London
Mark E. Robinson
Hugh and Josseline Langmuir Centre for Myeloma Research, Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London
Valentina S. Caputo
Hugh and Josseline Langmuir Centre for Myeloma Research, Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London
Alexia Katsarou
Hugh and Josseline Langmuir Centre for Myeloma Research, Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom; Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Foundation Trust, London
Nikolaos Trasanidis
Hugh and Josseline Langmuir Centre for Myeloma Research, Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London
Xiaolin Xiao
Hugh and Josseline Langmuir Centre for Myeloma Research, Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London
Ioannis V. Kostopoulos
Hugh and Josseline Langmuir Centre for Myeloma Research, Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom; Section of Animal and Human Physiology, National and Kapodestrian University of Athens, Department of Biology, School of Science, Athens
Deena Iskander
Hugh and Josseline Langmuir Centre for Myeloma Research, Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom; Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Foundation Trust, London
Irene Roberts
Department of Paediatrics and MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford and BRC Blood Theme, NIHR Oxford Biomedical Centre, Oxford
Pritesh Trivedi
Department of Cellular and Molecular Pathology, Northwest London Pathology, Imperial College Healthcare NHS Trust, London
Holger W. Auner
Hugh and Josseline Langmuir Centre for Myeloma Research, Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom; Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Foundation Trust, London
Kikkeri Naresh
Department of Cellular and Molecular Pathology, Northwest London Pathology, Imperial College Healthcare NHS Trust, London
Aristeidis Chaidos
Hugh and Josseline Langmuir Centre for Myeloma Research, Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom; Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Foundation Trust, London
Anastasios Karadimitris
Hugh and Josseline Langmuir Centre for Myeloma Research, Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom; Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Foundation Trust, London
Multiple myeloma is a malignancy of plasma cells initiated and driven by primary and secondary genetic events. However, myeloma plasma cell survival and proliferation might be sustained by non-genetic drivers. Z-DNA-binding protein 1 (ZBP1; also known as DAI) is an interferon-inducible, Z-nucleic acid sensor that triggers RIPK3-MLKL-mediated necroptosis in mice. ZBP1 also interacts with TBK1 and the transcription factor IRF3 but the function of this interaction is unclear, and the role of the ZBP1-IRF3 axis in cancer is not known. Here we show that ZBP1 is selectively expressed in late B-cell development in both human and murine cells and it is required for optimal T-cell-dependent humoral immune responses. In myeloma plasma cells, the interaction of constitutively expressed ZBP1 with TBK1 and IRF3 results in IRF3 phosphorylation. IRF3 directly binds and activates cell cycle genes, in part through co-operation with the plasma cell lineage-defining transcription factor IRF4, thereby promoting myeloma cell proliferation. This generates a novel, potentially therapeutically targetable and relatively selective myeloma cell addiction to the ZBP1-IRF3 axis. Our data also show a noncanonical function of constitutive ZBP1 in human cells and expand our knowledge of the role of cellular immune sensors in cancer biology.